RESERVIH32NCT03940521
Bioclinical Evaluation of 2 Biomarkers of Aviremic HIV-1 in CD4+ T Cells of Adults Undergoing Treatment
StatusCompleted
PhaseNot specified
Primary completion
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 13 versions: 13 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 13 words Show 4 more changesShow less
- Trial completed
- Final enrollment: 30 participants (planned 48)
- Study completion date changed from estimate of Sep 2026 to Sep 24, 2026
- Secondary endpoints: details revised at 14 of 19 entries
- Minor Trial status: Recruiting to Active, Not Recruiting
- Primary completion date changed from estimate of Sep 2025 to Sep 30, 2025
- Site details revised
- Notable Primary completion date: Sep 2024 to Sep 2025
- Study completion date: Sep 2025 to Sep 2026
- Site contact updated
- Minor Study completion date: Sep 2024 to Sep 2025
- Secondary endpoints: 17 to 19
- Notable Primary and study completion dates: Sep 2023 to Sep 2024v9
Show 7 earlier versionsHide 7 earlier versions
- Notable Primary and study completion dates: Sep 2022 to Sep 2023v8
- Minor Primary and study completion dates: Jun 2022 to Sep 2022v7
- Notable Primary and study completion dates: Jun 2021 to Jun 2022v6
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date changed from estimate of Sep 2020 to Sep 30, 2020
- Site details revised
- Notable Start date: Feb 2020 to Sep 2020
- Primary and study completion dates: Dec 2020 to Jun 2021
- Notable Start date: Sep 2019 to Feb 2020
- Primary and study completion dates: Sep 2020 to Dec 2020
- Notable Start date: May 2019 to Sep 2019
- Primary and study completion dates: May 2020 to Sep 2020
- Collaborator revised
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Percentage of CD4+ T cells expressing CD32 alone
Timeframe: Day 0
Percentage of CD4+ T cells expressing X alone
Timeframe: Day 0
Percentage of CD4+ T cells expressing both CD32 and X
Timeframe: Day 0
Quantification of proviral load
Timeframe: Day 0
Secondary (19)
Duration of infection prior to treatment
Duration of treatment
Year treatment commenced
Pre-therapeutic CD4 + T cell count
Pre-therapeutic viremia
Show 14 moreShow less
Change in CD4+ T cells over previous 2 years
Change in CD4+ T cells prior to treatment
Change in CD4+ T cells during treatment
Viremia at inclusion into the study
Viremia during the 2 previous years
Residual immune activation at inclusion into the study
Residual immune activation during the previous 2 years
Nature of current treatment
Co-infection with hepatitis C virus
Co-infection with hepatitis B virus
Co-infection with Cytomegalovirus
Co-infection with Epstein-Barr virus
Testing for intact proviral DNA
Circulating viral RNA sequence
Arms and interventions
HIV-A infected patients
Other: Bioclinical evaluation
Sites
1 site in 1 country
- CHU de NimesNîmes, France